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A B S T R A C T
Internationally, policy makers are increasingly focussed on reducing the detrimental consequences and rising
costs associated with unhealthy diets, inactivity, smoking, alcohol and other risk factors on the health of their
populations. This has led to an increase in the demand for evidence-based, cost-eﬀective Population Health
Interventions (PHIs) to reverse this trend. Given that research designs such as randomised controlled trials
(RCTs) are often not suited to the evaluation of PHIs, Natural Experiments (NEs) are now frequently being used
as a design to evaluate such complex, preventive PHIs. However, current guidance for economic evaluation
focusses on RCT designs and therefore does not address the speciﬁc challenges of NE designs. Using such gui-
dance can lead to sub-optimal design, data collection and analysis for NEs, leading to bias in the estimated
eﬀectiveness and cost-eﬀectiveness of the PHI. As a consequence, there is a growing recognition of the need to
identify a robust methodological framework for the design and conducting of economic evaluations alongside
such NEs. This paper outlines the challenges inherent to the design and conduct of economic evaluations of PHIs
alongside NEs, providing a comprehensive framework and outlining a research agenda in this area.
1. Introduction
Evaluating the eﬀectiveness and cost-eﬀectiveness of Population
Health Interventions (PHIs) has become an area of increasing interest
for researchers and decision makers. The UK's National Institute for
Health and Care Excellence (NICE) recently updated their methods
guidance to account for the speciﬁc requirements of PHIs economic
evaluation (e.g. broader cost-beneﬁt framework)(NICE, 2012, 2014). In
line with this, and very much in tune with the increased attention being
paid to the broader topic of ‘The Economics of Prevention’ (Merkur
et al., 2013) there has been an increase in both applied and methodo-
logical research on the economic evaluation of PHIs (Carter et al., 2009;
Edwards et al., 2013; Greco et al., 2016; McDaid et al., 2015; Tudor
Edwards and McIntosh, 2018; Weatherly et al., 2009).
Given the complex nature of many PHIs (Byford and Sefton, 2003;
Smith and Petticrew, 2010) in addition to the complexity of systems
within which they are delivered (Shiell et al., 2008), the identiﬁcation
of a credible causal eﬀect is a key methodological issue. Randomised
controlled trials (RCTs) have traditionally been regarded as the ‘gold
standard’ methodology for estimating the causal eﬀects of PHIs (Bonell
et al., 2011). The attractiveness of RCTs stems mainly from
randomisation, resulting in a ‘closed’ system, where researchers can
control exposure of participants to the intervention or to the control
group, eliminating or controlling those factors which have been re-
tained to be potential confounders (McDonnell et al., 2009). This results
in the most important advantage of RCTs, namely protection against
selection bias due to observed and unobserved diﬀerences between
treatment groups.
The researcher's control within an RCT design also extends to data
collection, which can be tailored to directly measure outcomes and
costs deemed to be relevant for the economic evaluation, as well as
identify potential confounders, that may need to be adjusted for, to
increase the precision of estimates.
However, randomisation might be neither practical, nor ethical for
PHIs, which are often not amenable to standard evaluation metho-
dology (Craig et al., 2008; Manca and Austin, 2008). Furthermore,
randomisation per se does not guarantee unbiased estimates of average
treatment eﬀects (ATEs) in every setting, (for example because of
practical failures to balance treatment and control groups or non-ad-
herence to treatment), thus ruling out the superiority of RCT with re-
spect to other methodologies to estimate the causal eﬀect (Deaton and
Cartwright, 2018). In such situations, natural experiments (NEs) can
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provide a viable alternative ‘vehicle’ for evaluation and economic
evaluation.
NEs can be deﬁned as “naturally occurring circumstances in which
subsets of a population have diﬀerent level of exposure to a supposed
causal factor, in a situation resembling an actual experiment where
human subjects would be randomly allocated to groups”(Last et al.,
2001). Unlike RCTs, NEs have a non-randomised design, where as-
signment to intervention cannot be controlled by the researcher, in-
stead the ‘intervention’ and ‘control’ groups are distinguished with re-
spect to observable and unobservable factors that may be related to the
outcome of interest (Deeks et al., 2003). Non-randomisation represents
a threat to internal validity, and a credible source of exogenous varia-
tion (e.g. random geographical and temporal variations in the avail-
ability of the intervention) is required to be able to identify the true
causal eﬀect (Meyer, 1995). In NEs, since the researcher cannot control
the source of randomness, the use of statistical designs and methodol-
ogies to deal with any resulting selection bias is advocated.
Despite arguably lower internal validity however NEs have the po-
tential for a higher external validity and higher “real world” relevance
than RCTs (Baltussen et al., 1999). For these reasons, this methodology
is increasingly being adopted for the evaluation of PHIs (Craig et al.,
2017). Existing guidance for designing, conducting and reporting eco-
nomic evaluations alongside RCTs (Drummond et al., 2015; Glick et al.,
2007; Husereau et al., 2013) do not address the speciﬁc challenges of
economic evaluation alongside NEs. In addition, existing literature on
conducting evaluations of NEs is scant and focuses on eﬀectiveness only
(e.g. Craig et al. (2017)). A related literature explores speciﬁc statistical
and econometric issues inherent to non-randomised studies, for eco-
nomic evaluations (Kreif et al., 2013a; Rovithis, 2013), but does not
explore the speciﬁc issues related to PHIs.
Following general RCT guidelines does not account for the speciﬁc
challenges of NEs in the design and conduct of economic evaluation of
PHIs such as identifying appropriate sources of linked data from the
early stage of design, encompassing methodologies to reduce selection
bias into a cost-eﬀectiveness framework and incorporating externalities
and spatial spillovers using observational data sources. This could lead
to a biased estimation of the causal eﬀect of the intervention thus
lowering the quality of evidence on eﬀectiveness and cost-eﬀectiveness.
Drawing on equivalent standards available for reporting and pre-
senting the results of economic evaluation alongside RCTs (Husereau
et al., 2013), this paper formally contrasts established methods and
guidance for conducting cost-eﬀectiveness analysis (CEA) alongside
RCTs in a bid to emphasise key diﬀerences with NEs. In doing so, we
review existing literature, identify gaps in existing methodological re-
search and provide a framework to guide the researcher from the early
design phase through to conducting the economic evaluation, including
a set of recommended best practices: the selection of multiple com-
parisons groups; identiﬁcation of the most appropriate sources of data
to conduct the economic evaluation; appropriate sensitivity analysis
using diﬀerent comparison groups/diﬀerent methodologies; use of de-
cision modelling; inclusion of an economic logic model. From this ex-
ercise we develop a critical appraisal checklist with the aim to outline
the speciﬁc requirements for designing and conducting economic eva-
luations alongside NEs. This checklist can also be used as a practical
tool for improving the quality and consistency of economic evaluations
alongside NEs.
2. Methods
A targeted scoping review of existing literature and reporting
guidelines was carried out to identify the key methodological issues
inherent to the economic evaluation of PHIs alongside NEs (details are
provided in the online appendix, A2).
This literature review is accompanied by a critical review of the
most common reporting guidelines: CHEERS (Husereau et al., 2013),
STROBE (Von Elm et al., 2014) and TREND (Des Jarlais et al., 2004).
CHEERS summarizes a comprehensive set of well-established best
practices covering economic evaluations alongside RCTs. STROBE and
TREND, while not considering economic evaluation, cover non-rando-
mised PHIs and observational studies framework, respectively.
All three guidelines were critically reviewed in terms of their ap-
plicability and relevance for economic evaluations in NEs and synthe-
sised to identify best practices for reporting economic evaluations in
NEs. Every item listed in the three guidelines has been critically as-
sessed in relation to existing literature on NEs and PHIs e.g. (Craig
et al., 2017; Drummond et al., 2007; Lorgelly et al., 2010; Petticrew
et al., 2005; Weatherly et al., 2009) and good design, conduct and re-
porting standards for RCTs (Drummond et al., 2015; Glick et al., 2007;
Petrou and Gray, 2011). Only the items which were identiﬁed to be
relevant to evaluate PHIs alongside NEs were retained, while items
speciﬁc to RCTs or to other frameworks (e.g. observational studies ex-
ploring the association between a risk factor and a health outcome)
were discarded. An iterative approach was used to adapt and reﬁne
existing reporting standards to our speciﬁc NE focus.
The output of the scoping review was a critical appraisal checklist of
good practice for designing and conducting economic evaluations
alongside NEs. The checklist comprises a set of recommendations,
corresponding to ten broad items, which have been described in rela-
tion to the challenges for the economic evaluation alongside NEs with
the view of emphasising key diﬀerences with respect to RCTs. Concrete
examples of economic evaluations alongside NEs from the literature,
when available, have been used throughout the paper to exemplify
adherence to this suggested set of best practices. The checklist has been
critically reﬂected upon by applying it to the economic evaluation of a
case study, the Healthy Start Voucher (HSV) scheme (Dundas et al.,
2014b), whose evaluation and economic evaluation has been funded by
the NIHR Public Health Research. A description of the HSV case study
and a practical application of the checklist to this speciﬁc case study
have been provided in the supplementary appendix A1.
3. Results
The scoping review resulted in the identiﬁcation of four broad sets
of literature: i)research considering speciﬁc challenges in the economic
evaluation of PHIs (e.g. outcome measurement; intersectoral costs and
consequences; equity), but not speciﬁc to NEs, e.g. (Drummond et al.,
2007; Lorgelly et al., 2010; Smith and Petticrew, 2010; Weatherly et al.,
2009) ii) methodological research describing speciﬁc issues related to
the reduction of selection bias inherent to non-randomised studies in a
cost-eﬀectiveness framework, (e.g Kreif et al. (2013a); Manca and
Austin (2008)); iii)research describing the beneﬁts and challenges of
using NEs in PHIs, but not speciﬁcally referring to economic evaluation
(e.g. Craig et al. (2017); Petticrew et al. (2005)); iv)case studies of
economic evaluation of PHIs in a non-randomised context, (e.g.(Alfonso
et al. (2015); Leyland et al. (2017)). The analysis of reporting guide-
lines, complemented with a focussed revision of the literature, has re-
vealed a complete lack of comprehensive guidance on how to design
economic evaluations of PHIs alongside NEs. Table 1 lists items iden-
tiﬁed from this review.
As shown in Table 1, RCTs and NEs diﬀer for most items, however
for items which do not diﬀer, we refer readers to existing CHEERS
guidelines (Husereau et al., 2013). With many of the items listed
inTable 1 being correlated (e.g. the choice of an appropriate time
horizon relates to data availability, outcomes and costs) these were
grouped into ten categories pertinent to the design and conduct of
economic evaluations alongside NEs. Building on these ten items, a
critical appraisal checklist was developed addressing speciﬁc require-
ments for designing and conducting economic evaluations alongside
NEs (Table 2). The following sections describe the items presented in
the checklist, highlighting challenges, item-speciﬁc diﬀerences with the
RCT framework and providing practical examples.
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3.1. Category 1: data sources and measurement
It is usually unfeasible or unpractical in a NE setting to conduct
individual patient-level data collection tailored to the speciﬁc require-
ments for a health economic evaluation. Hence, using multiple, some-
times linked, observational data sources (e.g. surveys, registries, ad-
ministrative records or census data) will likely represent standard
practice. The choice of observational data sources should be justiﬁed in
relation to their capability to capture the broad spectrum of inter-
sectoral cost and consequence impacts often associated with PHIs (item
1.1.1). Furthermore, suitability of data sources in relation to the chosen
statistical approaches to reduce selection bias (e.g. longitudinal study
for a before/after approach; adequacy of sample size; availability of
suitable instruments for Instrumental Variable (IV) approach) should be
explicitly justiﬁed (item 1.1.2).
Leyland et al. (2017) evaluated the Health in Pregnancy (HiP) grant,
a universal conditional cash transfer, introduced for women reaching
the 25th week of pregnancy, with the aim of improving birth weight
and other birth outcomes. They used several data sources including a
maternity and neonatal database, morbidity records, mother's obstetric
records to capture relevant outcomes (e.g. birthweight; gestation at
booking, booking before 25 weeks) and costs (e.g. hospitalizations and
delivery costs) for all registered birthsacross the pre-intervention, in-
tervention and post-intervention period. The period covered by the
linked data was suﬃciently long to exploit temporal variation, and
compare outcomes in periods immediately after the introduction of the
HiP grant with those periods before its introduction and after its
withdrawal.
The use of administrative data can often represent an advantage
over primary data collection, by overcoming issues of loss to follow-up
and low response rates, which can represent considerable challenges
when evaluating PHIs targeted towards disadvantaged populations
(Petticrew et al., 2005). Using routinely collected administrative data is
also likely to reduce measurement error and mitigate challenges of
recall bias inherent in survey data. Administrative data arguably pro-
vides fairly precise and objective estimates of healthcare usage and
costs incurred by the NHS, the healthcare provider, society and the
individual (Husain et al., 2012). Furthermore, observational data may
be available for a longer time span than data collected alongside short
follow up RCTs. This allows the researcher to track the identiﬁed target
population both prospectively and retrospectively (Husain et al., 2012).
Despite these advantages, there are challenges such as bureaucratic
procedures, anonymization, privacy and conﬁdentiality requirements
which may cause delays in data availability (item 1.2).
In addition to handling attrition and missing values (item 1.3), the
researcher has to address issues which are more speciﬁc to observa-
tional data such as measurement errors in confounding variables, due to
discrepancies between the timing of the intervention and period of data
availability (item 1.4). Whilst the methodology employed to handle
missing data (e.g. multiple imputation) is often reported in economic
evaluations of PHIs alongside NEs (e.g. (Dundas et al., 2014a; Leyland
et al., 2017), only few examples address the possible bias arising from
speciﬁc issues related to observational data. For example, Alfonso et al.
(2015) address the potential bias stemming from diﬀerent data sources
(household survey and health facility register) used to capture the main
outcome pre and post intervention.
3.2. Category 2: setting and location
Unlike RCTs, where the researcher decides the target population
and location, in a NE framework, setting and location are ﬁxed and
determined by the intervention or policy being evaluated. The target
population may be deﬁned by a policy-maker (who sets eligibility cri-
teria of the programme), potentially inﬂuenced by social or political
priorities. For example, a high maternal mortality rate motivated the
intervention evaluated by Alfonso et al. (2015), while concerns related
to the health of mothers of low socioeconomic background lead to the
design of the HiP evaluated by (Leyland et al., 2017). The researcher
needs to state these social and political priorities (item 2.1).
The use of secondary data sources typically allows the assessment of
eﬀectiveness and cost eﬀectiveness of the intervention over larger
sample size (often the entire population) than would be available in an
RCT, but these sources might also restrict the choice of target popula-
tion. For example, the choice of Scottish mothers even if the policy has
been implemented throughout the UK as target population for the
economic evaluation of HiP (Leyland et al., 2017) was driven not only
by the availability of high quality routine data, but also by the speciﬁc
characteristics of Scotland in terms of concentration of deprivation
Table 1
Reporting guidelines.
Item diﬀers between RCTs and NEs Item is reported in the guideline
CHEERS TREND STROBE
Background/objectives Yes Yes Yes Yes
Target population Yes Yes Yes Yes
Sample size Yes No Yes Yes
Subgroup deﬁnition and analysis Yes Yes Yes Yes
Setting and location Yes Yes Yes Yes
Study perspective Yes Yes No No
Comparators Yes Yes Yes No
Time horizon/length of follow-up Yes Yes Yes Yes
Data sources/measurement Yes No No Yes
Choice of health outcomes Yes Yes Yes Yes
Measurement and valuation of preference based outcomes Yes Yes No No
Estimating resources and costs Yes Yes No No
Currency, price, date and conversion No Yes No No
Analytical methods Yes Yes Yes Yes
Methods to address confounding Yes No Yes Yes
Variables (outcomes, exposure, predictors, potential confounders, eﬀect modiﬁers) Yes No No Yes
Bias and methodology to correct bias Yes No Yes Yes
Missing data imputation methods No Yes Yes Yes
Study parameters No Yes No No
Incremental costs and outcomes No Yes No No
Characterising uncertainty No Yes No Yes
Characterising heterogeneity No Yes Yes Yes
Discount rate No Yes No No
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Table 2
Checklist for the economic evaluation of PHIs alongside NEs.
Item description Has the study complied with the
item?
YES No NA
1. Data sources and measurement
1.1 The data used and the reason(s) why it has been chosen has been identiﬁed, stated and described in relation to:
1.1.1 all relevant intersectoral outcomes and costs being captured
1.1.2 implementation of the chosen statistical design
1.2 The application to routinely collected administrative data has been done on time to avoid delays in conducting economic
evaluations (e.g. due to bureaucratic procedures, anonymization, privacy and conﬁdentiality requirements).
1.3 The study recognize and address attrition and missing data and its consequences for the health economics analysis (bias)
1.4 The study recognize and address measurement errors (e.g. due to discrepancies between the timing of the intervention
and period of data availability) and its consequences for the health economics analysis (bias)
2. Setting and location
2.1 Setting and location are stated and explained in relation to social and political priorities
2.2 The source of secondary data that best meets the economic evaluation needs in terms of setting and location has been
stated
2.3 Concurrent interventions have been:
2.3.1 Identiﬁed
2.3.2 Tackled with appropriate statistical analysis (e.g. robustness checks; subsample analysis)
2.4 Potential spillovers/externalities eﬀects have been:
2.4.1 Identiﬁed through the usage of an economic evaluation logic model
2.4.2 Addressed through appropriate sensitivity analysis
3. Choice of comparators
3.1 The choice of comparators is justiﬁed in relation to reduction of selection bias due to non-randomisation, the unit of
assignment (individual or aggregate) and data availability
3.2 The existence of potential spillovers/crossovers has been considered in the choice of comparators
3.3 Multiple intervention/control groups have been used to examine sensitivity of the economic evaluation to multiple
sources of bias
4. Subgroups
4.1 If equity concerns are included in the economic evaluation, subgroups are deﬁned in relation to distributional concerns
4.2 Potential behavioural responses (e.g. ‘nudge eﬀects’), have been identiﬁed and measured
5. Outcome
5.1 An economic evaluation model mapping routinely collected intermediate outcomes to QALYs has been developed, using
additional evidence from systematic reviews to identify utility values.
5.2 An economic evaluation framework such as CCA, CBA or MCDA has been chosen and justiﬁed
6. Costs
6.1 Costing has been done considering a societal perspective
6.2 When unit cost data associated to a speciﬁc resource use are not available, a decision rule (e.g. usage of the average unit
cost of the most frequently used service) is explained and justiﬁed.
6.3 When speciﬁc categories of resource use are not publicly available a decision rule is explained and justiﬁed.
6.4 The opportunity cost of transfer payments (i.e. transfer of resources from the government to beneﬁciaries, with a null net
impact on society) has been identiﬁed and measured
7. Time horizon
7.1 Linked data are adequate to capture the presence of long term eﬀects
7.2 Appropriate discount rates, in line with the most up to date guidance have been applied
8. Inclusion of a logic model
8.1. A logic model has been developed, and it addresses:
8.1.1 Time horizon(e.g. eﬀects that would 'carry over' after the intervention ended)
8.1.2 possible subgroups eﬀect
8.1.3 externalities and spillovers
9. Analytical methods
9.1 The researchers have justiﬁed the source of variation in the exposure to the intervention, choosing a design and a
statistical approach which is appropriate in relation to that source of variation.
9.1.1 If the study is a before after design frequent measurements of data on long pre-treatment time periods have been collected
9.2 Multiple statistical designs have been employed to examine the sensitivity of economic evaluation to multiple sources of
bias
9.3 The list of potential confounders has been presented
9.4 Causal eﬀects have been interpreted considering potential contaminating policies
9.5 The interpretation of the estimated cost-eﬀectiveness is in line with the estimated parameter
9.6 The methodologies to reduce selection bias have been incorporated into an economic evaluation framework, considering
health economics-speciﬁc challenges (i.e. skewed outcome and cost data, correlated outcome and cost data).
10. Uncertainty and sensitivity analysis
10.1 All sources of uncertainty have been identiﬁed using appropriate methods (e.g. probabilistic sensitivity analysis;
tornado diagrams)
10.2 Cost-eﬀectiveness results according to the diﬀerent analytical choices have been reported
10.3 Sensitivity analysis has been done in relation to:
10.3.1 assumptions made in relation to unit cost
10.3.2 potential spillovers
10.3.3 comparators
10.3.4 diﬀerent designs
10.3.5 econometric methodology chosen
10.3.6 unobserved confounding
10.3.7 transfer payments and administrative costs
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(Leyland et al., 2017). Hence, the choice of a target population that best
meets the evaluation needs is important (item 2.2).
Identifying who is aﬀected by the PHI in a NE framework is often
not straightforward, especially in relation to the complexity of PHIs,
which usually involve several interacting components (Craig et al.,
2008). Moreover in a real-world setting, several concurrent, interacting
policy interventions may be in place at the same time making it chal-
lenging to separately identify the eﬀects of the diﬀerent policies. Such
concurrent interventions should be identiﬁed (item 2.3.1), and mea-
sured by employing appropriate statistical analyses (e.g. robustness
checks; subsample analysis) (item 2.3.2). In the HiP study, the in-
troduction of the ban on smoking in enclosed public spaces in Scotland
was considered as a potentially contaminating policy and an analysis
that restricted pre-treatment periods to after the introduction of the
smoking ban was carried out. (Leyland et al., 2017).
The possibility of externalities (when producing or consuming a
good/intervention causes a positive or negative impact on third par-
ties), spillovers (wider health beneﬁts), and ‘cross-over’ eﬀects or
‘contamination’ (individuals from the control group migrating towards
the intervention group) while also possible in RCT settings, poses an
increased challenge for NEs (Petticrew et al., 2005). First, any treat-
ment ‘contamination’ can lead to misclassiﬁcation of individuals into
intervention and control groups, Second, even if the intervention and
controls groups are well-deﬁned, the eﬀect a PHI may aﬀect several
groups, or extend to individuals or areas, which are beyond the scope of
the intervention. While general frameworks to incorporate spill-over
eﬀects within economic evaluations have been developed (e.g. Al-
Janabi et al. (2011)), these might require additional data collection
outwit the NEs framework which typically makes use of existing ob-
servational data sources.
The existence of cost and consequence spill-overs and externalities
could be identiﬁed using an economic evaluation logic model, (de-
scribed in Section 3.8) (item 2.4.1), and addressed through a sensitivity
analysis that would include a broad set of multi-sectoral costs and
outcomes into the analysis (item 2.4.2).
3.3. Category 3: comparators
The choice of intervention and control group is a major challenge in
non-randomised studies (Petticrew et al., 2005). In an evaluation of
NEs, this needs to be aligned with the choice of methodology to reduce
selection bias due to non-randomisation, the unit of assignment (in-
dividual or aggregate) and data availability (item 3.1).
It is important to choose the control group which maximises internal
validity, increasing a researcher's ability to attribute diﬀerences in
outcomes and costs to the intervention, and not to other confounding
factors. In this regards, the existence of spill-overs and contamination,
should be identiﬁed in the early stages of study design, in order to
identify the most appropriate sources of secondary data (item 3.2).
Hence, the use of multiple intervention/control groups is recommended
to examine the sensitivity of the economic evaluation to multiple
sources of bias (Craig et al., 2012; Meyer, 1995) (item 3.3).
3.4. Category 4: subgroups
Since many PHIs are often directed towards the reduction of health
inequalities (Cookson, 2016) identiﬁcation of subgroups within an
economic evaluation of PHIs alongside NEs could be informed by
considerations of equity, in addition to eﬃciency considerations (item
4.1). In the case of HiP, given the potential of such an intervention to
have a greater eﬀect in deprived subgroups, a subgroup analysis by
level of deprivation was a key component of the evaluation (Leyland
et al., 2017).
Considerations of equity in economic evaluations can be achieved
by identifying appropriate subgroups, incorporating value judgments or
employing methods that explicitly incorporate equity in the decision
making process such as Distributional Cost-Eﬀectiveness analysis
(DCEA) (Asaria et al., 2016) or extended cost-eﬀectiveness analysis
(Verguet et al., 2015).
Methods which speciﬁcally address equity concerns, such as DCEA,
are preferred to subgroup analysis if there is potential that the inter-
vention generates an unfair health distribution. However, these
methods might be more burdensome in terms of data and computa-
tional requirement and may not be feasible when using observational
data.
Identiﬁcation of subgroups would also allow researchers to disen-
tangle potential behavioural responses, such as ‘nudge eﬀects’ that may
arise alongside the intervention. While such nudge eﬀects are rarely
investigated alongside economic evaluations, they could be used for
developing more eﬀective PHIs. It is recommended that researchers
complement the traditional economic evaluation methods with the
additional of behavioural economic insights by identifying and mea-
suring the existence of potential nudge eﬀects within the PHI (item 4.2).
3.5. Category 5: outcomes
Within prospectively designed economic evaluations alongside
RCTs researchers typically include a preference based measure of out-
come such as the EuroQol EQ-5D (EuroQol Group, 2015) to facilitate
calculation of Quality Adjusted Life Years (QALYs). Furthermore,
measures that capture spillover QOL eﬀects (e.g. to family members,
carers etc.) such as the Carer Experience Scale (CES) (Al-Janabi et al.,
2011) can be included. However, without researcher input in the design
of outcomes, preference-based outcomes may not be routinely col-
lected, relying on intermediate outcomes. As such, researchers typically
focus on the causal eﬀect of the program on intermediate outcomes
(e.g. birth weight in the HiP (Leyland et al., 2017). These could sub-
sequently be mapped to generic health measures such as QALYs or
Disability Adjusted Life Years (DALYs) using a decision analytical
model (Briggs et al., 2006)(item 5.1).
A focus on unidimensional outcomes may be too narrow in PHIs
where a battery of multi-sector outcomes may be relevant for inclusion,
using a broader societal perspective including beneﬁts to patients,
carers and the whole society. For example, PHIs aimed at improving
infant mental health result in long term improvements in infant health,
educational attainment and employment prospects (Deidda et al.,
2018)). This justiﬁes collecting a wide range of outcomes, and the use
of broader evaluation frameworks such as cost-beneﬁt analysis (CBA)
(Tudor Edwards and McIntosh, 2018), cost-consequence analysis (CCA)
(as recommended by the NICE public health economic evaluation gui-
dance) or multi-criteria decision analysis (Marsh et al., 2016) (MCDA).
Speciﬁcally, MCDA would facilitate the identiﬁcation and measurement
of a plethora of outcomes which are relevant to decision makers,
weighting and valuing each of them with methods such as discrete
choice experiments (DCEs).
While these methods can be also used in a RCT framework to
complement the primary cost-utility analysis-, an increased use of
available secondary data in NE's is likely to justify further use of CBA,
CCA and MCDA (item 5.2).
3.6. Category 6: estimating resources and costs
A societal perspective is recommended best practice for economic
evaluations of PHIs (NICE, 2012, 2014), given the inter-sectoral costs
often associated with PHIs (item 6.1).
Routinely collected data may not allow for the identiﬁcation of
speciﬁc resource use data; e.g. individuals may be asked about hospital
length of stay, without any detail on specialty or Health Related Group
(HRG). Conditional on the available information from several sources
(administrative data, published reports and literature) we recommend
that the researcher employs a decision rule for such proxy valuation
such as using the average unit cost of the most frequently used service
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or choosing the maximum/minimum among a set of available unit costs
(items 6.2 and 6.3). The choice should reﬂect the compilation of a
standard ‘average’ unit cost.
Transfer payments (transfer of resources from the government to the
beneﬁciaries with null net impact on society) will not be included, even
when a broad societal perspective is considered, and the impact of the
intervention on how resources are distributed is not taken into account
(Byford et al., 2003). However, it may still be informative to identify
and measure the opportunity cost or ‘beneﬁts forgone’ of these pay-
ments in view of the value attached by the society to the redistribution
of wealth in sensitivity analyses (item 6.4).
3.7. Category 7: time horizon
The choice of a time horizon ought to account for the presence of
long term eﬀects that may ‘carry over’ after an intervention ended. This
is particularly relevant for PHIs, where the outcomes of such ‘pre-
ventive’ interventions may arise in the future. Unlike RCTs, where the
length of time horizon is often constrained (Manca and Austin, 2008),
and long term eﬀects can only be identiﬁed using extrapolation through
decision modelling, NE designs may facilitate a longer time horizon for
data collection. This would allow data to capture the, often elusive,
long term impacts of PHIs which may be incorporated into a long term
decision analytical model, developed following best practices for such
complex PHIs (Squires et al., 2016).
To this end, while eﬀects carrying over after the intervention end
are not speciﬁc to NEs, stating suitability of linked data to capture these
eﬀects within a NE framework is strongly recommended in order to
adequately take these eﬀects into account.
If it is likely that an intervention has an eﬀect that would ‘carry
over’ after an intervention ends, the time horizon should be adjusted to
take these eﬀects into account, and should be reﬂected in the choice of
adequate data. If the available data do not allow to follow-up for a time
span that would capture such eﬀects, or if the information about long
term outcomes of the intervention is not present, the use of external
sources is recommended (item 7.1).
In the event of longer term outcomes, discount rates in line with
most recent guideline (NICE, 2014) should be applied to costs and
beneﬁts (item 7.2).
3.8. Logic models and economic evaluations
Within the complex framework of PHIs and NEs, an economic
evaluation logic model (NICE, 2014) represents a useful tool to describe
anticipated causal pathways and inter-relationships of resource use and
outcomes, providing guidance the choice of data collection identifying
the behaviour change induced by the intervention, the factors that exert
inﬂuence on program eﬀectiveness and cost-eﬀectiveness at diﬀerent
levels (individual, social, group level)(e.g. (Deidda et al., 2018).
Despite its role in depicting complexity of PHIs evaluated alongside
NEs, thus potentially guiding the researcher from the early stages of
design, the economic evaluation logic model does not currently re-
present standard practice. Fig. 1 shows an illustrative example of the
logic model for the HSV project.
3.9. Category 8: analytical methods
3.9.1. Design elements and corresponding statistical approaches
While researchers evaluating a PHI using NE methods may not have
control over when, where and amongst whom an intervention has been
implemented, they will likely have some control over choosing design
elements of the evaluation that strengthen the credibility of the esti-
mated eﬀects. The control group within randomised studies provide the
counterfactual outcome (i.e. what would have happened to programme
participants, in the absence of the programme), whereas evaluations of
NEs need to construct it, typically involving design elements with
appropriate statistical approaches.
In order to create a credible design it is strongly recommended that
researchers understand and justify the source of variation in the ex-
posure to the intervention (item 9.1), which needs to have an exo-
genous element for credible causal inference (Meyer, 1995).
Diﬀerent sources of variation can lead to three distinct designs and
corresponding statistical and econometric approaches:
1. Designs using temporal and geographical variation: one-group be-
fore-after comparisons (Auer et al. (2016)); interrupted time series
(Leyland et al., 2017); diﬀerence-in-diﬀerence (DiD) (Nandi et al.
(2016)) and panel data methods (Pesko et al., 2016); synthetic
control approach (Abadie et al., 2010). For before-after designs,
identifying a potential control group and collecting frequent mea-
surements of data on long pre-treatment time periods (Wagenaar
et al., 2001) is a recommended best practice to oﬀset the con-
founding role of potential anticipatory eﬀects as well as other po-
licies introduced at the same time (item 9.1.1).
2. Designs using individual level variation, where “nature” provides a
variation in treatment assignment that resembles randomisation in
the controlled situation of an actual experiment: IV eg. (Ichida et al.,
2013; Yen et al., 2008); regression discontinuity design (RDD)
(Andalón, 2011; Calonico et al., 2014; Imbens and Lemieux, 2008;
Ludwig and Miller, 2007)
3. Designs aiming to construct a control group which best approx-
imates an ideal randomised experiment: matching (e.g. propensity
score matching and more recent covariate-balancing multivariate
matching methods) (Caliendo and Kopeinig (2008); Stuart (2010);
Zubizarreta, 2012) Melhuish et al. (2008)).
Often, more than one design is embedded in the evaluation (Craig
et al., 2012), or diﬀerent designs are combined. Exploring the sensi-
tivity of cost-eﬀectiveness results to approaches used to reduce the se-
lection bias inherent to non-randomised studies allow examination of
the sensitivity of economic evaluation to multiple sources of bias and
strengthens the credibility of results (item 9.2). If all results are in the
same direction with a similar magnitude, this gives the analyst in-
creased conﬁdence that the intervention had a true eﬀect.
Most of the research designs previously described corresponds to
well deﬁned statistical and econometric methods (reviewed for example
in (Athey and Imbens, 2017; Imbens and Rubin, 2015; Imbens and
Wooldridge, 2009). For each design and statistical method, it is re-
commended to specify the list of potential confounders to control for,
using substantive knowledge on the relationship between the inter-
vention and the outcomes, and the mechanism of the assignment to the
intervention (item 9.3).
In line with recommendations provided for item 2.3, if any con-
current intervention is identiﬁed, the causal eﬀect should be interpreted
with caution, in consideration of potential contaminating policies (item
9.4).
The design of a NE has implications for several aspects of the as-
sociated economic evaluation, especially the choice of an appropriate
statistical method and the interpretation of the estimated eﬀectiveness
and cost-eﬀectiveness parameters (e.g. IV and RDD only facilitate the
estimation of local ATEs, which can be interpreted as incremental cost
and incremental eﬀectiveness parameters among a speciﬁc population).
Interpretation of the estimated eﬀectiveness and cost-eﬀectiveness
results needs to be aligned to the estimated parameters (ATE, ATE on
the Treated, Local ATE). When combining estimated parameters from
diﬀerent research design and data sources, or when reporting results
using diﬀerent statistical methods researchers need to transparently
report which of these parameters are identiﬁed (item 9.5).
3.9.2. Implementation of the statistical approaches in an economic
evaluation setting
Existing literature regarding the implementation of some of the
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above listed statistical approaches (e.g. Stuart (2010) and Caliendo and
Kopeinig (2008) Jacob et al. (2012)) rarely cover the speciﬁc challenges
of economic evaluations, such as skewed and correlated cost and out-
come data. Extensions of statistical approaches for the purposes of
economic evaluation is a growing strand of methodological literature,
for example, IV approaches have been extended to handle binary out-
come data (Terza et al., 2008) as well as correlated cost and outcome
data (DiazOrdaz et al., 2018).
Regression and matching methods can handle correlated data using
a Bayesian framework (Nixon and Thompson (2005); Manca and Austin
(2008)), as well as the non-parametric bootstrap (Sekhon and Grieve
(2012) (Kreif et al. (2012); Kreif et al. (2013b)). Furthermore, ﬂexible
parametric and semiparametric approaches have been proposed to
handle skewed cost distributions (Jones et al., 2015) and outcomes, e.g.
quality of life data (Basu and Manca, 2012). For complex interventions,
beyond the correlated costs and outcomes, a further challenge is
handling potentially correlated multiple outcomes (Teixeira-Pinto and
Normand, 2009).
If needed, clustering needs to be handled, e.g. using multilevel
modelling or two-stage bootstrap, following recommendations that
extend these methods for economic evaluations (Gomes et al., 2012).
Given the importance of routinely collected data, as well as survey data
in the evaluation of NEs, missing data is expected to be an important
challenge for economic evaluation (See recommendations in Category
1)(Faria et al., 2014). The economic evaluation of PHIs alongside NEs
should encompass methodologies to reduce selection bias into an
econometric framework considering health economics-speciﬁc chal-
lenges (item 9.6).
3.10. Category 9: uncertainty & sensitivity analysis
The previous sections have outlined a range of sources of structural
or methodological uncertainty (Briggs et al., 2006) when conducting
economic evaluations alongside NEs. As for the RCT framework, all
sources of uncertainty need to be identiﬁed, using recommended
methods such as probabilistic sensitivity analysis, tornado diagrams
(item 10.1), and reporting cost-eﬀectiveness results according to dif-
ferent analytical choices (item 10.2). However, the researcher needs to
address also additional sources of uncertainty speciﬁc to NEs that (item
10.3). Indeed, exploring sensitivity to several sources of unit costs (item
10.3.1) and assessing the sensitivity of potential spillovers (item 10.3.2)
are common to RCT frameworks. However, exploring sensitivity to the
diﬀerent choice of comparators (item 10.3.3), designs (item 10.3.4),
econometric approaches (item 10.3.5), unobserved confounding (item
10.3.6) and description of transfer payments (item 10.3.7) are addi-
tional sensitivity checks that needs to be performed in a NE framework.
4. Discussion
In the paper we have outlined the need for methodological guidance
for conducting economic evaluations alongside NEs. Our guidance is
based on the most recent methodological advances and has identiﬁed a
set of best practices as a ﬁrst step towards the development of a com-
prehensive framework. We have exempliﬁed how the political and so-
cial aims inherent to PHIs and the selection bias inherent to the design
of NEs pose unique challenges for health economic evaluations. For
example, reliance on existing data sources does not allow the researcher
to design data collection instruments to include ‘ﬁnal’, utility-based
outcomes, but oﬀers advantages in terms of population
Fig. 1. Health Economics logic models.
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representativeness. We have also highlighted that conducting economic
evaluations of PHIs alongside NEs poses challenges which should be
considered in the early design stage, in order to enhance the quality of
the economic evaluation. For example, data linkage can overcome
limitations of individual data sources by extending available data to
also include a broad set of outcomes and costs. Similarly, long-term
decision modelling can help linking short term, intermediate outcomes
(e.g. children's birthweight) with longer term ﬁnal outcomes (e.g.
QALYs, life expectancy). Being able to address these challenges ade-
quately and to robustly analyse NEs can be highly advantageous in
settings where RCTs are unsuitable.
Our paper adds to available reporting guidelines (CHEERS,
CONSORT, STROBE), recognizing the lack of a unique, comprehensive
framework addressing the speciﬁc challenges of designing and con-
ducting economic evaluations alongside NEs. We have focused on using
NEs, rather than RCTs, to evaluate PHIs and highlighting the additional
challenges arising from economic evaluation. Whilst recognizing that
the available literature only provides a partial view of the challenges
related to economic evaluation of PHIs alongside, the current work
adapts the available literature, re-interpreting existing best practice in a
systematic way.
This paper provides the ﬁrst framework for conducting economic
evaluations of PHIs alongside NEs, and oﬀers a set of recommendations
that can support researchers undertaking transparent and accurate
evaluations, in line with existing NICE guidelines on economic eva-
luations of PHIs. Our proposed framework aims to improve and stan-
dardise the way economic evaluations of PHIs alongside NEs are con-
ducted, providing a benchmark against which studies can be compared,
thus has the potential to improve the overall quality and transparency
of future evaluations. Furthermore, the set of guidelines we have de-
veloped is consistent with existing NICE guidance on conducting eco-
nomic evaluations of PHIs, by recommending the use of a societal
perspective, as well as alternative frameworks to CUA (e.g. CBA and
CCA) to capture the battery of multi-sectoral outcomes of PHIs.
This paper also contributes to and expands existing studies (e.g.
(Chalkidou et al., 2008; Lorgelly et al., 2010; Weatherly et al., 2009)
focussing on and drawing out the beneﬁts and challenges related to
using NEs to evaluate PHIs, by highlighting methodological challenges
such as matters of equity, the publicness (i.e. non excludability) of
many PHIs, handling multiple outcomes and dealing with externalities.
While this paper has focused on NE methods for evaluating PHIs, rather
than clinical or healthcare interventions, further research should ex-
plore the challenges of conducting economic evaluations in those set-
tings.
While the majority of methodological considerations speciﬁc to
economic evaluation alongside NEs are not novel in themselves, our
contribution lies in their collective use to deliver a framework for
analysis to guide decision making. The paper has provided a starting
point for a new and emerging research area, by identifying key areas for
future research, including, but not limited to: developing well-estab-
lished econometric methodologies to encompass approaches to reduce
the selection bias inherent to NEs into an economic evaluation frame-
work; developing a logic/conceptual modelling framework to simplify
the intricacy inherent to economic evaluation of PHIs alongside NEs,
guiding the researcher from early design to model development; ex-
plore suitability of alternative economic evaluation frameworks such as
MCDA or CCA to evaluate PHIs in the presence of multiple, inter-sec-
toral outcomes; development of methodologies to incorporate long term
inter-sectoral spillovers into economic evaluation.
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